Drug Discovery World

APRIL 5, 2023

We will be collaborating closely with the consortium’s network of scientists to help fuel the world’s discovery engine in the fight against cancer.” Members contribute their expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and in vivo and in vitro models for oncology.

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

Drug Discovery World

JULY 3, 2023

This was centred around pre-clinical models (in vitro and in vivo) to support discovery and development, re-entering the fray with costimulatory agonists, and clinical development strategies for combinations with immune cell engagers​.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

Drug Discovery World

JUNE 30, 2023

Select mature stem cell lines can then be used in small-scale in vitro assays, and proven biochemical and phenotypic screens supporting target validation and deconvolution studies. Through the use of human induced pluripotent stem cells (iPSCs) derived cells, we can improve translation and reduce risk of clinical failure.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Drug Discovery World

JANUARY 23, 2023

Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

MAY 9, 2023

The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable alternatives are available, has highlighted the inadequacy of animal models most often used for in vivo research. Cancer is far more complex than the sum of its parts. Mice have long been heroes of preclinical cancer research.

Development 52

Development Drugs In-Vivo Clinical Trials 52

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

OCTOBER 27, 2023

With cues from a diverse population of tissue-specific cell types, extracellular matrix proteins, and biomechanical forces, cells grown in organ-chips closely emulate their in vivo counterparts and replicate tissue-level functions. But can organ-chips entirely replace other models? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Approaches to Pharmacokinetic Analysis.

Production 133

Production Bioavailability In-Vivo Bioequivalency 133

FDA Law Blog

FEBRUARY 2, 2023

The law defines this term to mean “a test conducted in vitro, in silico, or in chemico, or a nonhuman in vivo test that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug.” Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2). 42 U.S.C. § 262(k)(2)(A)(i)(I).

Clinical Trials 64

Clinical Trials Clinical Trials In-Vivo In-Vitro 64

Drug Discovery World

JULY 22, 2022

By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. Patient-derived xenografts (PDX) of melanoma were grafted into hIL2 mice, and TILs derived from the same melanoma patient were reactivated and expanded in vitro with IL2 and used to treat the PDX engrafted in the mice. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Drug Discovery World

AUGUST 3, 2022

Currently, only a small number of CPP-based oligonucleotide delivery examples have been reported for in vivo application. In a recent publication from scientists at the University of Bordeaux, a CPP-based nanoparticles approach was reportedly used to deliver siRNA into cancer cells of solid tumours. Covalent (thiol-maleimide) 7.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

APRIL 3, 2023

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Pharmaceutical Technology

JANUARY 4, 2023

Findings from a study, which was conducted by Transcenta and Shanghai Jiao Tong University scientists on TST003 to treat androgen receptor-negative/low prostate cancer, were published by Nature Cancer in May last year. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Drug Discovery World

JANUARY 12, 2023

Scientists use complex gene editing and disease modeling systems to gain insights on the potential of CRISPR. . Scientists use complex gene editing and disease modeling systems to gain insights on the potential of CRISPR. . The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases.

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Drug Discovery World

JULY 22, 2022

The company recently implemented CDD Vault registration system and ELN as its central repository for storing, characterizing and managing its libraries, structure activity relationship (SAR) data, and in vitro and other experimental and screening assay data. .

Drugs 98

Drugs In-Vitro In-Vivo Clinical Trials 98

Drug Discovery World

NOVEMBER 8, 2023

Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, on: ‘Evaluation of Fcab-drug conjugates as a novel antibody-based format for targeted drug delivery’.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

FEBRUARY 15, 2023

Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

JANUARY 24, 2024

Fibrocor is on track to complete all IND-enabling work to support IND filing and initiation of clinical trials in 2024. Phase I of the clinical program will dose healthy volunteers with single ascending doses of FIB992 before proceeding to a multiple ascending dose study where the drug is administered for a two-week period.

Research 59

Research Gene Expression Drugs Development 59

Drug Discovery World

OCTOBER 17, 2022

For pharma and biotech companies – whether working on small or large molecule drugs, or cell and gene therapies – this means empowering scientists with better and faster data management approaches, best practices, and leading technologies so they can pinpoint new molecules and formulations and modify existing ones more easily and quickly.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

Roots Analysis

OCTOBER 19, 2023

Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ). These are mainly transmitted through air, water, living organisms, and food.

Bacteria 40

Bacteria Production In-Vivo In-Vitro 40

Drug Discovery World

JANUARY 23, 2023

This circumvents several technical challenges inherent to the genetic manipulation of differentiated cells in ex vivo culture or intact tissues. In cell therapy, regenerative and adoptive immunotherapies continue to bridge the gap between genetic engineering strategies and their clinical application.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

FEBRUARY 22, 2024

According to Medicine Discovery Catapult, these include: “Navigating the complexity of the CNS; understanding the disease pathology, and accessing predictable in vitro and in vivo cell models 2 ”. Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In million deaths worldwide” 1.

Drugs 59

Drugs Gene Clinical Trials Clinical Trials 59

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. ” ABOUT ALLOY THERAPEUTICS Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all.

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Our chemists and formulation scientists review the properties of new drug candidates and “work their magic” to develop formulations that improve the exposure profile of the compound. Quotient Sciences helps biotech and pharma customers in the development and optimization of drug products.

Development 246

Development Drugs Bioavailability In-Vivo 246